Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock

Immix Biopharma (IMMX) closed a $150 million underwritten registered offering of common stock, selling 16,778,524 shares at $8.94 per share.

Rhea-AI Summary

Immix Biopharma (IMMX) closed a $150 million underwritten registered offering of common stock, selling 16,778,524 shares at $8.94 per share.

According to Immix Biopharma, net proceeds were about $140.65 million. The financing included leading U.S. biotechnology institutional investors and mutual funds.

Positive

• Gross common stock offering size of approximately $150 million
• Net proceeds of about $140.65 million to Immix Biopharma
• Financing participation from leading U.S. biotechnology institutional investors and mutual funds

Negative

• Issuance of 16,778,524 new common shares implies shareholder dilution

Argus May 26 session

+0.68% close to close Open Argus

Details

News Market Reaction – IMMX

In the May 26 session, IMMX gained 0.68%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement confirms closing of a $150 million underwritten common stock offering at $8.94 per...

Analysis

This announcement confirms closing of a $150 million underwritten common stock offering at $8.94 per share, with net proceeds of about $140.65 million. The transaction draws on IMMX’s effective $750,000,000 Form S-3 shelf and lifts shares outstanding to roughly 69.8M. Investors may weigh dilution against a strengthened balance sheet that supports NXC-201 development. Key items to monitor include future shelf takedowns, trial milestones, and cash burn versus the enlarged capital base.

Key Figures

Gross offering size: $150 million Net offering proceeds: $140.65 million Shares offered: 16,778,524 shares +5 more

Gross offering size

$150 million

Underwritten common stock offering announced May 22, 2026

Net offering proceeds

$140.65 million

Net of underwriting discounts and expenses for May 2026 deal

Shares offered

16,778,524 shares

Common stock sold in May 2026 underwritten offering

Offering price

$8.94 per share

Public price for May 2026 common stock financing

Shares outstanding post-offer

69,790,616 shares

As disclosed in May 21, 2026 424B5 prospectus supplement

Shelf capacity

$750,000,000

Maximum aggregate amount under Form S-3 shelf filed Jan 9, 2026

Quarterly net loss

$10.1 million

Net loss for three months ended March 31, 2026 (10-Q)

Cash & investments

$90.6 million

Cash, cash equivalents and short-term investments as of March 31, 2026

Previous Offering Reports

3 past events · Latest: May 21

Same Type 3 events

1. May 21

   Offering pricing

   24h Move

   -3.0%

   Priced $150M common stock offering at $8.94 per share.

2. Dec 09

   Offering closing

   24h Move

   +2.0%

   Closed upsized $100M stock and pre-funded warrant offering.

3. Dec 07

   Offering pricing

   24h Move

   +10.6%

   Priced upsized $100M common stock and pre-funded warrant deal.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

underwritten registered offering, shelf registration statement, form s-3, prospectus supplement, +1 more

5 terms

underwritten registered offering financial

"announced the closing of its previously announced underwritten registered offering of 16,778,524 shares"

An underwritten registered offering is a public sale of a company’s securities that has been officially filed with regulators and is sold through one or more investment banks that agree to buy the securities and resell them to investors. Think of it like a store hiring a wholesaler who guarantees to buy the stock on the shelf so the store can raise cash immediately; for investors it signals structured distribution but can dilute existing shares and affect market price depending on size and demand.

shelf registration statement regulatory

"offered and sold pursuant to a “shelf” registration statement on Form S-3 (File No. 333-292665)"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

form s-3 regulatory

"“shelf” registration statement on Form S-3 (File No. 333-292665), including a base prospectus"

Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.

prospectus supplement regulatory

"A prospectus supplement and accompanying prospectus describing the terms of the registered offering was filed"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

base prospectus regulatory

"registration statement on Form S-3 (File No. 333-292665), including a base prospectus, filed with the U.S."

A base prospectus is a detailed document that provides essential information about a financial offering, such as a bond or share issue. It acts like a comprehensive guide for investors, explaining what the investment involves, the risks involved, and how the process works. This helps investors make informed decisions before committing their money.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

– Financing includes leading U.S. biotechnology institutional investors and mutual funds –

LOS ANGELES, CA, May 22, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a global leader in AL Amyloidosis, today announced the closing of its previously announced underwritten registered offering of 16,778,524 shares of its common stock at a price to the public of $8.94 per share. The net proceeds to Immix from the offering, after deducting the underwriting discounts, commissions and other offering expenses, were approximately $140.65 million.

The financing includes leading U.S. biotechnology institutional investors and mutual funds.

Morgan Stanley acted as the lead book-running manager and BofA Securities acted as book-running manager for the offering. LifeSci Capital, Mizuho and Needham & Company acted as co-lead managers for the offering.

The securities in the registered offering were offered and sold pursuant to a “shelf” registration statement on Form S-3 (File No. 333-292665), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on January 9, 2026, and declared effective on January 22, 2026. A prospectus supplement and accompanying prospectus describing the terms of the registered offering was filed with the SEC and is available on its website at www.sec.gov. Copies of the prospectus supplement and the accompanying prospectus relating to the offering may also be obtained from: Morgan Stanley & Co. LLC, attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, by phone: 1-866-718-1649 or by email: prospectus@morganstanley.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Immix Biopharma, Inc.

Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a global leader in AL Amyloidosis. AL Amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead produces toxic light chains, clogging up the heart, kidney and liver, causing organ failure and death. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a “digital filter” that is designed to filter out non-specific activation. NXC-201 teaches the immune system to recognize and eliminate the source of the toxic light chains. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a potentially registrational design. NXC-201 has been awarded Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA.

Contacts
Mike Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com 

Company Contact
Gabriel Morris, CFO
irteam@immixbio.com 

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Immix Biopharma (IMMX) announce about its $150 million stock offering on May 22, 2026?

Immix Biopharma announced the closing of a $150 million underwritten registered offering of common stock. According to Immix Biopharma, the company sold 16,778,524 shares at $8.94 per share to institutional biotechnology investors and mutual funds.

How many shares did Immix Biopharma (IMMX) issue and at what price in its May 2026 offering?

Immix Biopharma issued 16,778,524 common shares at $8.94 per share in the underwritten offering. According to Immix Biopharma, this registered transaction generated gross proceeds of about $150 million before underwriting discounts and expenses.

What were the net proceeds to Immix Biopharma (IMMX) from the May 2026 underwritten offering?

Net proceeds to Immix Biopharma from the offering were approximately $140.65 million. According to Immix Biopharma, this figure is after deducting underwriting discounts, commissions and other offering expenses from the $150 million gross common stock sale.

Who managed Immix Biopharma’s (IMMX) May 2026 underwritten common stock offering?

Morgan Stanley acted as lead book-running manager and BofA Securities as book-running manager. According to Immix Biopharma, LifeSci Capital, Mizuho and Needham & Company served as co-lead managers for the registered common stock financing.

Was Immix Biopharma’s (IMMX) May 2026 stock sale conducted under an SEC shelf registration?

Yes, the offering was conducted under a shelf registration statement on Form S-3. According to Immix Biopharma, the registration (File No. 333-292665) was filed January 9, 2026 and declared effective January 22, 2026 by the SEC.